Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
The South-Eastern Norway Regional Health Authority hereby announces a call for applications for research projects and research activities starting in 2017.
The total funding available for this call is approximately 100 million Norwegian kroner.
Application deadline is Tuesday, September 6th 2016 kl. 16:00.
Marina Vietri from Institute for Cancer Research and Centre for Cancer Biomedicine is awarded H.M. the King's Gold Medal for best thesis of the Faculty of Medicine.
She will receive the medal at the annual celebration of the University of Oslo in the University Aula on 2nd September.
In order to stimulate excellent research and draw attention to the hospital's extensive research activity, Oslo University Hospital reward outstanding publications regularly.
Six research groups were awarded for their excellent papers published during the second half-year of 2015 during a ceremony June 17th. Each group was given NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.
The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.
Professor Atle Bjørnerud from the Intervention Centre at Oslo University Hospital has been selected "Innovator of the Month" by the South-Eastern Norway Regional Health Authority for the month of May.
The main focus of the research performed in his group is perfusion analysis of brain tumors with the overall aim of providing better tools for early, accurate diagnosis and monitoring treatment response.
Three scientists received awards for their outstanding research activities at a ceremony taking place at Oslo University Hospital May 27th.
The major prize - the "Excellent Researcher Award" - went to professor Pål Aukrust.
Therese Seierstad and Espen Melum both received the "Early Career Award".
The prize money - 300.000 and 150.000 NOK respectively - is earmarked for research activities. This prize is distributed anually in order to honour excellent scientific work.
Erlend Strønen and Johanna Olweus from the Department of Immunology at the Institute for Cancer Research and the K.G. Jebsen Centre for Cancer Immunotherapy are first and joint last author respectively on a paper recently (May 19th) published in Science (journal impact factor 33.6), entitled "Targeting of cancer neoantigens with donor-derived T cell receptor repertoires".
The international research team - based in Oslo, Amsterdam and Copenhagen - has made a breakthrough methodological development in generating broad and tumour-specific T-cell immune responses based on a novel allogeneic approach. This is a powerful technological advancement which can in the relatively near future be subjected to clinical testing.
Håvard Danielsen and Erik Fosse receive Lighthouse project grants from the Norwegian Research Council
Oslo University Hospital heads projects DoMore! led by Håvard Danielsen from the Institute for Cancer Genetics and Informatics and BIGMED led by Erik Fosse from the Intervention Centre project receive Lighthouse project grant from the Norwegian Research Council's IKTPLUSS area of commitment. The funding for each project is 60 million NOK over a five-year period.
There were 76 research teams competing for the prestigious grant and only three winners- The third project is INTROMAT, led by Tine Nordgreen from UiB.
The DoMore! team is composed of experts within several fields, including digital imaging, processing, robotics, pathology, cell biology, surgery and oncology, both in Norway and abroad.
The vision behind the BIG data MEDical solution (BIGMED) is to lay the foundation for an ICT platform that addresses the analytic bottlenecks for the implementation of precision medicine, and paves the way for novel big data analytics.
"Intelligent needle tracking using ultrasound imaging for improved minimally invasive interventions" supported by EU
Philips, B.Braun and Oslo University Hospital are partnering in the EU funded INTUI-VIEW project to develop, validate, and bring to the market an intelligent needle tracking technology using ultrasound imaging. The aim of this project is to reliably visualize the needle position in relation to the patient’s anatomy, under ultrasound guidance. The INTUI-VIEW project has been granted €2.36 million.
The participants representing OUH in the project are Axel R. Sauter and Leiv-Arne Rosseland (photo) from the Division of Emergencies and Critical Care at Oslo University Hospital. OUH will receive € 75000 for use in this project, which will be running approximately for 3 years.
The most comprehensive analysis to date of somatic (acquired) mutations, across whole-genome sequences for breast cancer, is reported in a paper published in the May 2nd edition of Nature (journal impact factor 41.5).
Miriam R. Aure, Anita Langerød, Ole Christian Lingjærde, and Anne-Lise Børresen-Dale from the "Molecular biology of breast cancer group" at the Department of Cancer Genetics has contributed substantially to the study.
A related paper, published in Nature Communications, explores how these mutations relate to aspects of genome structure. Together, the studies highlight the repertoire of genes and mutational processes involved in breast cancer and move us closer to a more complete account of the genetic basis of the disease.
2015 has been a very good year for ICR, and areas for further improvement include increases in collaboration with clinical researchers, partnerships and coordinator roles in more successful EU grants, and strengthened international visibility.
Read all the details in the recently published annual report.
Annuncement of research funding from South-East Norway regional health authority for 2017
Jun 23, 2016
Jun 22, 2016
Jun 22, 2016
Prof. Gunnar Sæter – Director of Institute for Cancer Research
Jun 21, 2016
Jun 18, 2016
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
Plasma membrane repairs by small GTPase Rab3a
J Cell Biol, 213 (6), 613-5
More selected publications